Skip to Content

Esterified Estrogens / Methyltestosterone Dosage

Medically reviewed on December 25, 2017.

Applies to the following strengths: 0.625 mg-1.25 mg; 1.25 mg-2.5 mg

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for Postmenopausal Symptoms

For treatment of moderate to severe vasomotor symptoms associated with the menopause in patients not improved by estrogen alone:
Esterified estrogens-medroxyprogesterone 1.25 mg-2.5 mg oral tablets: one tablet orally once a day.
or
Esterified estrogens-medroxyprogesterone 0.625 mg-1.25 mg oral tablets: one or two tablets orally once a day.

The lowest dose that will control symptoms should be chosen and medication should be discontinued as promptly as possible. Administration should be cyclic (e.g., three weeks on and one week off). Attempts to discontinue or taper medication should be made at three to six month intervals.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Contraindicated in liver dysfunction or disease.

Precautions

US BOXED WARNINGS:
-CARDIOVASCULAR DISORDERS AND PROBABLE DEMENTIA: Estrogen with or without progestins should not be used for prevention of cardiovascular disease. The Women's Health Initiative (WHI) study reported an increased risk of deep vein thrombosis (DVT), pulmonary embolism (PE), stroke, invasive breast cancer, and myocardial infarction (MI) in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE) (0.625 mg) combined with medroxyprogesterone acetate (MPA) (2.5 mg), relative to placebo. The WHI Memory Study (WHIMS) study reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral CE plus MPA relative to placebo. It is unknown whether this finding applies to younger postmenopausal women or women taking estrogen alone therapy. Other doses of CE with MPA, and other combinations and dosage forms of estrogens and progestins were not studied in the WHI clinical trials and, in the absence of comparable data, these risks should be assumed to be similar. Due to these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.
-ENDOMETRIAL CANCER: Estrogens increase the risk of endometrial cancer. Close clinical surveillance of all women taking estrogens is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent doses.
-USE DURING PREGNANCY: Use of female sex hormones, both estrogens and progestogens, during early pregnancy may seriously damage the offspring. It has been shown that females exposed in utero to diethylstilbestrol, a non-steroidal estrogen, show an increased risk of developing later in life a form of vaginal or cervical cancer that is ordinarily extremely rare. This risk has been estimated as not greater than 4 per 1000 exposures. Furthermore, a high percentage of such exposed women (from 30 to 90 percent) have been found to have vaginal adenosis, epithelial changes of the vagina and cervix. Although these changes are histologically benign, it is not known whether they are precursors of malignancy. Although similar data are not available with the use of other estrogens, it cannot be presumed they would not induce similar changes. In the past, female sex hormones have been used during pregnancy in an attempt to treat threatened or habitual abortion. There is considerable evidence that estrogens are ineffective for these indications, and there is no evidence from well controlled studies that progesterones are effective for these uses. If esterified estrogens and methyltestosterone full strength or esterified estrogens and methyltestosterone half strength is used during pregnancy, or if the patient becomes pregnant while taking this drug, she should be apprised of the potential risks to the fetus, and the advisability of pregnancy continuation.

This drug is not recommended for use in children.

Consult WARNINGS section for additional precautions.

Dialysis

Data not available

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide